Neovacs' TNF-Kinoid moves into Phase II in Crohn's disease
This article was originally published in Scrip
Neovacs has begun a Phase II multicentre international clinical trial of its TNF-alpha Kinoid product for patients with Crohn's disease. Following the results of its Phase I/II study announced at the beginning of December 2010, the company received the go-ahead from regulatory authorities and ethics committees in France and Belgium. Neovacs' CEO, Guy Charles Fanneau de la Horie, told Scrip that the company was expecting trial approvals in a number of other European countries and that patient recruitment there, as well as in France and Belgium, would be completed by the end of March 2011.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.